<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="10.17917/C7BC78" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><h2>NCL Method GTA-2: Hep G2 Hepatocarcinoma Cytotoxicity Assay</h2><hr><p>This protocol describes the cytotoxicity testing of nanoparticle formulations in human hepatocarcinoma cells (Hep G2), as part of the in vitro NCL preclinical characterization cascade. The protocol utilizes two methods for estimation of cytotoxicity, 3-(4,5-Dimethyl-2-thiazolyl)2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction and lactate dehydrogenase (LDH) release.</p><h3>File name: protocols/20241210_19-22-19-573_NCL_Method_GTA-2.pdf</h3><h3>DOI: <a href = http://dx.doi.org/10.17917/C7BC78>http://dx.doi.org/10.17917/C7BC78</a></h3</body></html>